BofA analyst Jason Zemansky raised the firm’s price target on Cytokinetics (CYTK) to $63 from $62 and keeps a Neutral rating on the shares. The Q3 report and call were “uneventful” and unlikely to impact the thesis much, says the analyst, who cites adjusted operating expense projections, offset by the change in net cash, for the firm’s price target increase.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics’ Market Uncertainty and Competitive Pressures Lead to Hold Rating
- Cytokinetics’ Q3 2025: Progress in Cardiac Therapies
- Cytokinetics reports Q3 EPS ($2.55), consensus ($1.57)
- Cytokinetics price target raised to $70 from $55 at JPMorgan
- CYTK Earnings Report this Week: Is It a Buy, Ahead of Earnings?